[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQx4HVDxC2uQu08XBDd5ldmIVwou8XAWBCaJNqBH_zH4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":69,"rows":76},"Northside Hospital, Inc.",[4],26,false,8,0,783,13,6,[14,17,20,22,24,27,29,32],{"name":15,"count":16},"Myelodysplastic Syndromes",5,{"name":18,"count":19},"Leukemia",4,{"name":21,"count":19},"Lymphoma",{"name":23,"count":19},"Multiple Myeloma",{"name":25,"count":26},"Myelodysplastic Syndrome",3,{"name":28,"count":26},"Acute Myeloid Leukemia",{"name":30,"count":31},"Myeloproliferative Disorders",2,{"name":33,"count":31},"Multiple Myeloma and Plasma Cell Neoplasm",[35,40,45,50,55,60,64],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05909059","CAR T-cell Therapy in Patients With Renal Dysfunction","2026-08-31","Fludarabine",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04237623","GM-CSF With Post-Transplant Cyclophosphamide","2026-09-18","Sargramostim",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05519579","Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia","2026-11-01","Methotrexate",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06046248","Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease","2026-12-31","Belumosudil",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide","2027-06-30","Tacrolimus",{"nctId":61,"briefTitle":62,"date":63,"intervention":39},"NCT02828592","Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","2027-08-31",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07511062","Axatilimab Combined With Decitabine\u002FVenetoclax for the Treatment of TP53-mutated AML","2029-08-01","Decitabine",[70,71,72,73,74,75],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[77,181,227,266,312,342,363,381,399,417,435,463,485,503,533,563,589,611,633,651,669,693,711,738,756,774,801,819],{"intervention":78,"totalTrials":79,"cells":80},"Cyclophosphamide",7,{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":82,"activeCount":9},[],{"trials":84,"activeCount":9},[],{"trials":86,"activeCount":26,"soonestReadout":38},[87,106,120,131,150,159,168],{"nctId":88,"briefTitle":89,"status":90,"phases":91,"primaryCompletion":92,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":99},"NCT00787761","Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","COMPLETED",[72],"2010-07","2012-05","2007-04",24,[30,97,18,21,33,15,98],"Kidney Cancer","Myelodysplastic\u002FMyeloproliferative Diseases",[100,101,102,103,104,105],"anti-thymocyte globulin","busulfan","cyclophosphamide","fludarabine phosphate","methotrexate","tacrolimus",{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":116},"NCT00818961","Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer","TERMINATED",[72],"2011-03","2012-03","2005-05",36,[18,21,15,98],[117,118,119,101,102,103,104,105],"alemtuzumab","graft-versus-tumor induction therapy","rituximab",{"nctId":121,"briefTitle":122,"status":90,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"NCT00782379","Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer",[72],"2011-04","2012-04","2008-10",20,[18,21,15],[101,102,103,130,105],"mycophenolate mofetil",{"nctId":132,"briefTitle":133,"status":90,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":148},"NCT02581007","Reduced Intensity Conditioning Transplant Using Haploidentical Donors",[72],"2019-11-05","2020-12-28","2015-10-26",25,[140,141,25,142,143,144,145,146,147,23],"Chronic Myelogenous Leukemia","Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Lymphocytic Leukemia","Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma","Myelofibrosis","CMML",[39,149,78],"Melphalan",{"nctId":61,"briefTitle":62,"status":151,"phases":152,"primaryCompletion":63,"completion":153,"start":154,"enrollment":127,"conditions":155,"interventions":157},"RECRUITING",[72],"2028-08-31","2016-09-09",[156],"Severe Aplastic Anemia",[39,78,158,78],"Rabbit ATG",{"nctId":56,"briefTitle":57,"status":151,"phases":160,"primaryCompletion":58,"completion":161,"start":162,"enrollment":127,"conditions":163,"interventions":166},[72],"2028-06-30","2025-07-03",[164,165],"Hematologic Disease and Disorders","Hematopoietic Cell Transplant",[59,78,167],"Mycofenolate mofetil",{"nctId":36,"briefTitle":37,"status":151,"phases":169,"primaryCompletion":38,"completion":63,"start":170,"enrollment":127,"conditions":171,"interventions":174},[72],"2024-11-18",[172,23,173],"Non-hodgkin Lymphoma,B Cell","Acute Lymphoblastic Leukemia, Adult",[39,78],{"trials":176,"activeCount":9},[],{"trials":178,"activeCount":9},[],{"trials":180,"activeCount":9},[],{"intervention":39,"totalTrials":16,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":221,"PHASE4":223,"NA":225},{"trials":184,"activeCount":9},[],{"trials":186,"activeCount":9},[],{"trials":188,"activeCount":31,"soonestReadout":38},[189,193,203,207,217],{"nctId":132,"briefTitle":133,"status":90,"phases":190,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":191,"interventions":192},[72],[140,141,25,142,143,144,145,146,147,23],[39,149,78],{"nctId":194,"briefTitle":195,"status":196,"phases":197,"primaryCompletion":38,"completion":63,"start":198,"enrollment":9,"conditions":199,"interventions":200},"NCT06337331","Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant","WITHDRAWN",[72],"2024-08-31",[28,15],[201,68,39,202],"Venetoclax","Busulfan",{"nctId":61,"briefTitle":62,"status":151,"phases":204,"primaryCompletion":63,"completion":153,"start":154,"enrollment":127,"conditions":205,"interventions":206},[72],[156],[39,78,158,78],{"nctId":208,"briefTitle":209,"status":90,"phases":210,"primaryCompletion":211,"completion":212,"start":213,"enrollment":127,"conditions":214,"interventions":215},"NCT02771197","Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant",[72],"2022-08-03","2023-07-31","2016-09-28",[28],[39,149,216],"Pembrolizumab",{"nctId":36,"briefTitle":37,"status":151,"phases":218,"primaryCompletion":38,"completion":63,"start":170,"enrollment":127,"conditions":219,"interventions":220},[72],[172,23,173],[39,78],{"trials":222,"activeCount":9},[],{"trials":224,"activeCount":9},[],{"trials":226,"activeCount":9},[],{"intervention":105,"totalTrials":16,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":230,"activeCount":9},[],{"trials":232,"activeCount":9},[],{"trials":234,"activeCount":259,"soonestReadout":58},[235,239,243,247,255],{"nctId":88,"briefTitle":89,"status":90,"phases":236,"primaryCompletion":92,"completion":93,"start":94,"enrollment":95,"conditions":237,"interventions":238},[72],[30,97,18,21,33,15,98],[100,101,102,103,104,105],{"nctId":107,"briefTitle":108,"status":109,"phases":240,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":241,"interventions":242},[72],[18,21,15,98],[117,118,119,101,102,103,104,105],{"nctId":121,"briefTitle":122,"status":90,"phases":244,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":245,"interventions":246},[72],[18,21,15],[101,102,103,130,105],{"nctId":248,"briefTitle":249,"status":109,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":16,"conditions":253,"interventions":254},"NCT00827099","Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer",[72],"2009-11","2006-06",[30,18,21,33,15],[100,103,149,130,105],{"nctId":56,"briefTitle":57,"status":151,"phases":256,"primaryCompletion":58,"completion":161,"start":162,"enrollment":127,"conditions":257,"interventions":258},[72],[164,165],[59,78,167],1,{"trials":261,"activeCount":9},[],{"trials":263,"activeCount":9},[],{"trials":265,"activeCount":9},[],{"intervention":267,"totalTrials":19,"cells":268},"Rituximab",{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":270,"activeCount":9},[],{"trials":272,"activeCount":9},[],{"trials":274,"activeCount":259,"soonestReadout":53},[275,284,288,299],{"nctId":276,"briefTitle":277,"status":90,"phases":278,"primaryCompletion":279,"completion":280,"start":124,"enrollment":138,"conditions":281,"interventions":283},"NCT01161628","Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)",[72],"2014-01","2015-07",[282],"Chronic Graft-versus-host Disease",[267],{"nctId":107,"briefTitle":108,"status":109,"phases":285,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":286,"interventions":287},[72],[18,21,15,98],[117,118,119,101,102,103,104,105],{"nctId":289,"briefTitle":290,"status":109,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT04235036","Ibrutinib and Rituxan for Chronic GVHD",[72],"2022-12-23","2019-12-16",15,[296],"Graft Vs Host Disease",[267,298],"Ibrutinib",{"nctId":51,"briefTitle":52,"status":151,"phases":300,"primaryCompletion":53,"completion":301,"start":302,"enrollment":138,"conditions":303,"interventions":305},[72],"2027-12-31","2024-01-29",[304],"Chronic Graft Versus Host Disease",[54,267],{"trials":307,"activeCount":9},[],{"trials":309,"activeCount":9},[],{"trials":311,"activeCount":9},[],{"intervention":104,"totalTrials":26,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":315,"activeCount":9},[],{"trials":317,"activeCount":9},[],{"trials":319,"activeCount":259,"soonestReadout":48},[320,324,328],{"nctId":88,"briefTitle":89,"status":90,"phases":321,"primaryCompletion":92,"completion":93,"start":94,"enrollment":95,"conditions":322,"interventions":323},[72],[30,97,18,21,33,15,98],[100,101,102,103,104,105],{"nctId":107,"briefTitle":108,"status":109,"phases":325,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":326,"interventions":327},[72],[18,21,15,98],[117,118,119,101,102,103,104,105],{"nctId":46,"briefTitle":47,"status":151,"phases":329,"primaryCompletion":48,"completion":330,"start":331,"enrollment":127,"conditions":332,"interventions":334},[72],"2026-12-01","2023-06-30",[333],"Acute Lymphoblastic Leukemia",[49,335],"Blinatumomab",{"trials":337,"activeCount":9},[],{"trials":339,"activeCount":9},[],{"trials":341,"activeCount":9},[],{"intervention":44,"totalTrials":259,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":345,"activeCount":9},[],{"trials":347,"activeCount":9},[],{"trials":349,"activeCount":259,"soonestReadout":43},[350],{"nctId":41,"briefTitle":42,"status":151,"phases":351,"primaryCompletion":43,"completion":43,"start":352,"enrollment":353,"conditions":354,"interventions":356},[72],"2020-05-18",38,[355],"Transplant-Related Hematologic Malignancy",[44],{"trials":358,"activeCount":9},[],{"trials":360,"activeCount":9},[],{"trials":362,"activeCount":9},[],{"intervention":335,"totalTrials":259,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":366,"activeCount":9},[],{"trials":368,"activeCount":9},[],{"trials":370,"activeCount":259,"soonestReadout":48},[371],{"nctId":46,"briefTitle":47,"status":151,"phases":372,"primaryCompletion":48,"completion":330,"start":331,"enrollment":127,"conditions":373,"interventions":374},[72],[333],[49,335],{"trials":376,"activeCount":9},[],{"trials":378,"activeCount":9},[],{"trials":380,"activeCount":9},[],{"intervention":158,"totalTrials":259,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":393,"PHASE4":395,"NA":397},{"trials":384,"activeCount":9},[],{"trials":386,"activeCount":9},[],{"trials":388,"activeCount":259,"soonestReadout":63},[389],{"nctId":61,"briefTitle":62,"status":151,"phases":390,"primaryCompletion":63,"completion":153,"start":154,"enrollment":127,"conditions":391,"interventions":392},[72],[156],[39,78,158,78],{"trials":394,"activeCount":9},[],{"trials":396,"activeCount":9},[],{"trials":398,"activeCount":9},[],{"intervention":167,"totalTrials":259,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":402,"activeCount":9},[],{"trials":404,"activeCount":9},[],{"trials":406,"activeCount":259,"soonestReadout":58},[407],{"nctId":56,"briefTitle":57,"status":151,"phases":408,"primaryCompletion":58,"completion":161,"start":162,"enrollment":127,"conditions":409,"interventions":410},[72],[164,165],[59,78,167],{"trials":412,"activeCount":9},[],{"trials":414,"activeCount":9},[],{"trials":416,"activeCount":9},[],{"intervention":54,"totalTrials":259,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":420,"activeCount":9},[],{"trials":422,"activeCount":9},[],{"trials":424,"activeCount":259,"soonestReadout":53},[425],{"nctId":51,"briefTitle":52,"status":151,"phases":426,"primaryCompletion":53,"completion":301,"start":302,"enrollment":138,"conditions":427,"interventions":428},[72],[304],[54,267],{"trials":430,"activeCount":9},[],{"trials":432,"activeCount":9},[],{"trials":434,"activeCount":9},[],{"intervention":68,"totalTrials":31,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":451,"PHASE3":457,"PHASE4":459,"NA":461},{"trials":438,"activeCount":9},[],{"trials":440,"activeCount":259,"soonestReadout":67},[441],{"nctId":65,"briefTitle":66,"status":442,"phases":443,"primaryCompletion":67,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},"NOT_YET_RECRUITING",[71],"2030-08-01","2026-08-01",32,[28,448],"TP53 Gene Mutation",[68,201,450],"Axatilimab",{"trials":452,"activeCount":9},[453],{"nctId":194,"briefTitle":195,"status":196,"phases":454,"primaryCompletion":38,"completion":63,"start":198,"enrollment":9,"conditions":455,"interventions":456},[72],[28,15],[201,68,39,202],{"trials":458,"activeCount":9},[],{"trials":460,"activeCount":9},[],{"trials":462,"activeCount":9},[],{"intervention":201,"totalTrials":31,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":473,"PHASE3":479,"PHASE4":481,"NA":483},{"trials":466,"activeCount":9},[],{"trials":468,"activeCount":259,"soonestReadout":67},[469],{"nctId":65,"briefTitle":66,"status":442,"phases":470,"primaryCompletion":67,"completion":444,"start":445,"enrollment":446,"conditions":471,"interventions":472},[71],[28,448],[68,201,450],{"trials":474,"activeCount":9},[475],{"nctId":194,"briefTitle":195,"status":196,"phases":476,"primaryCompletion":38,"completion":63,"start":198,"enrollment":9,"conditions":477,"interventions":478},[72],[28,15],[201,68,39,202],{"trials":480,"activeCount":9},[],{"trials":482,"activeCount":9},[],{"trials":484,"activeCount":9},[],{"intervention":450,"totalTrials":259,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":488,"activeCount":9},[],{"trials":490,"activeCount":259,"soonestReadout":67},[491],{"nctId":65,"briefTitle":66,"status":442,"phases":492,"primaryCompletion":67,"completion":444,"start":445,"enrollment":446,"conditions":493,"interventions":494},[71],[28,448],[68,201,450],{"trials":496,"activeCount":9},[],{"trials":498,"activeCount":9},[],{"trials":500,"activeCount":9},[],{"trials":502,"activeCount":9},[],{"intervention":101,"totalTrials":19,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":506,"activeCount":9},[],{"trials":508,"activeCount":9},[],{"trials":510,"activeCount":9},[511,515,519,523],{"nctId":88,"briefTitle":89,"status":90,"phases":512,"primaryCompletion":92,"completion":93,"start":94,"enrollment":95,"conditions":513,"interventions":514},[72],[30,97,18,21,33,15,98],[100,101,102,103,104,105],{"nctId":107,"briefTitle":108,"status":109,"phases":516,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":517,"interventions":518},[72],[18,21,15,98],[117,118,119,101,102,103,104,105],{"nctId":121,"briefTitle":122,"status":90,"phases":520,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":521,"interventions":522},[72],[18,21,15],[101,102,103,130,105],{"nctId":194,"briefTitle":195,"status":196,"phases":524,"primaryCompletion":38,"completion":63,"start":198,"enrollment":9,"conditions":525,"interventions":526},[72],[28,15],[201,68,39,202],{"trials":528,"activeCount":9},[],{"trials":530,"activeCount":9},[],{"trials":532,"activeCount":9},[],{"intervention":103,"totalTrials":19,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":557,"PHASE4":559,"NA":561},{"trials":536,"activeCount":9},[],{"trials":538,"activeCount":9},[],{"trials":540,"activeCount":9},[541,545,549,553],{"nctId":88,"briefTitle":89,"status":90,"phases":542,"primaryCompletion":92,"completion":93,"start":94,"enrollment":95,"conditions":543,"interventions":544},[72],[30,97,18,21,33,15,98],[100,101,102,103,104,105],{"nctId":107,"briefTitle":108,"status":109,"phases":546,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":547,"interventions":548},[72],[18,21,15,98],[117,118,119,101,102,103,104,105],{"nctId":121,"briefTitle":122,"status":90,"phases":550,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":551,"interventions":552},[72],[18,21,15],[101,102,103,130,105],{"nctId":248,"briefTitle":249,"status":109,"phases":554,"primaryCompletion":251,"completion":251,"start":252,"enrollment":16,"conditions":555,"interventions":556},[72],[30,18,21,33,15],[100,103,149,130,105],{"trials":558,"activeCount":9},[],{"trials":560,"activeCount":9},[],{"trials":562,"activeCount":9},[],{"intervention":149,"totalTrials":26,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":566,"activeCount":9},[],{"trials":568,"activeCount":9},[],{"trials":570,"activeCount":9},[571,575,579],{"nctId":248,"briefTitle":249,"status":109,"phases":572,"primaryCompletion":251,"completion":251,"start":252,"enrollment":16,"conditions":573,"interventions":574},[72],[30,18,21,33,15],[100,103,149,130,105],{"nctId":132,"briefTitle":133,"status":90,"phases":576,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":577,"interventions":578},[72],[140,141,25,142,143,144,145,146,147,23],[39,149,78],{"nctId":208,"briefTitle":209,"status":90,"phases":580,"primaryCompletion":211,"completion":212,"start":213,"enrollment":127,"conditions":581,"interventions":582},[72],[28],[39,149,216],{"trials":584,"activeCount":9},[],{"trials":586,"activeCount":9},[],{"trials":588,"activeCount":9},[],{"intervention":100,"totalTrials":31,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":592,"activeCount":9},[],{"trials":594,"activeCount":9},[],{"trials":596,"activeCount":9},[597,601],{"nctId":88,"briefTitle":89,"status":90,"phases":598,"primaryCompletion":92,"completion":93,"start":94,"enrollment":95,"conditions":599,"interventions":600},[72],[30,97,18,21,33,15,98],[100,101,102,103,104,105],{"nctId":248,"briefTitle":249,"status":109,"phases":602,"primaryCompletion":251,"completion":251,"start":252,"enrollment":16,"conditions":603,"interventions":604},[72],[30,18,21,33,15],[100,103,149,130,105],{"trials":606,"activeCount":9},[],{"trials":608,"activeCount":9},[],{"trials":610,"activeCount":9},[],{"intervention":130,"totalTrials":31,"cells":612},{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":627,"PHASE4":629,"NA":631},{"trials":614,"activeCount":9},[],{"trials":616,"activeCount":9},[],{"trials":618,"activeCount":9},[619,623],{"nctId":121,"briefTitle":122,"status":90,"phases":620,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":621,"interventions":622},[72],[18,21,15],[101,102,103,130,105],{"nctId":248,"briefTitle":249,"status":109,"phases":624,"primaryCompletion":251,"completion":251,"start":252,"enrollment":16,"conditions":625,"interventions":626},[72],[30,18,21,33,15],[100,103,149,130,105],{"trials":628,"activeCount":9},[],{"trials":630,"activeCount":9},[],{"trials":632,"activeCount":9},[],{"intervention":117,"totalTrials":259,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":645,"PHASE4":647,"NA":649},{"trials":636,"activeCount":9},[],{"trials":638,"activeCount":9},[],{"trials":640,"activeCount":9},[641],{"nctId":107,"briefTitle":108,"status":109,"phases":642,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":643,"interventions":644},[72],[18,21,15,98],[117,118,119,101,102,103,104,105],{"trials":646,"activeCount":9},[],{"trials":648,"activeCount":9},[],{"trials":650,"activeCount":9},[],{"intervention":118,"totalTrials":259,"cells":652},{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":654,"activeCount":9},[],{"trials":656,"activeCount":9},[],{"trials":658,"activeCount":9},[659],{"nctId":107,"briefTitle":108,"status":109,"phases":660,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":661,"interventions":662},[72],[18,21,15,98],[117,118,119,101,102,103,104,105],{"trials":664,"activeCount":9},[],{"trials":666,"activeCount":9},[],{"trials":668,"activeCount":9},[],{"intervention":670,"totalTrials":259,"cells":671},"Convalescent Plasma",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":673,"activeCount":9},[],{"trials":675,"activeCount":9},[],{"trials":677,"activeCount":9},[678],{"nctId":679,"briefTitle":680,"status":109,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":8,"conditions":684,"interventions":686},"NCT04408040","Use of Convalescent Plasma for COVID-19",[72],"2021-09-14","2020-07-14",[685],"COVID",[670],{"trials":688,"activeCount":9},[],{"trials":690,"activeCount":9},[],{"trials":692,"activeCount":9},[],{"intervention":298,"totalTrials":259,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":705,"PHASE4":707,"NA":709},{"trials":696,"activeCount":9},[],{"trials":698,"activeCount":9},[],{"trials":700,"activeCount":9},[701],{"nctId":289,"briefTitle":290,"status":109,"phases":702,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":703,"interventions":704},[72],[296],[267,298],{"trials":706,"activeCount":9},[],{"trials":708,"activeCount":9},[],{"trials":710,"activeCount":9},[],{"intervention":712,"totalTrials":259,"cells":713},"Palonosetron",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":715,"activeCount":9},[],{"trials":717,"activeCount":9},[],{"trials":719,"activeCount":9},[720],{"nctId":721,"briefTitle":722,"status":90,"phases":723,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT01370408","Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients",[72],"2016-03","2012-02",85,[728],"Chemotherapy-induced Nausea and Vomiting",[712,730,731],"ondansetron","Dexamethasone",{"trials":733,"activeCount":9},[],{"trials":735,"activeCount":9},[],{"trials":737,"activeCount":9},[],{"intervention":730,"totalTrials":259,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":741,"activeCount":9},[],{"trials":743,"activeCount":9},[],{"trials":745,"activeCount":9},[746],{"nctId":721,"briefTitle":722,"status":90,"phases":747,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":748,"interventions":749},[72],[728],[712,730,731],{"trials":751,"activeCount":9},[],{"trials":753,"activeCount":9},[],{"trials":755,"activeCount":9},[],{"intervention":731,"totalTrials":259,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":768,"PHASE4":770,"NA":772},{"trials":759,"activeCount":9},[],{"trials":761,"activeCount":9},[],{"trials":763,"activeCount":9},[764],{"nctId":721,"briefTitle":722,"status":90,"phases":765,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":766,"interventions":767},[72],[728],[712,730,731],{"trials":769,"activeCount":9},[],{"trials":771,"activeCount":9},[],{"trials":773,"activeCount":9},[],{"intervention":775,"totalTrials":259,"cells":776},"MLN9708",{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":795,"PHASE4":797,"NA":799},{"trials":778,"activeCount":9},[],{"trials":780,"activeCount":9},[],{"trials":782,"activeCount":9},[783],{"nctId":784,"briefTitle":785,"status":90,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":789,"conditions":790,"interventions":794},"NCT02169791","Nonmyeloablative Haploidentical Transplant Followed by MLN9708",[72],"2020-07-28","2014-07-15",29,[791,792,25,793,23],"Acute Leukemia","Chronic Leukemia","Lymphomas",[775],{"trials":796,"activeCount":9},[],{"trials":798,"activeCount":9},[],{"trials":800,"activeCount":9},[],{"intervention":216,"totalTrials":259,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":804,"activeCount":9},[],{"trials":806,"activeCount":9},[],{"trials":808,"activeCount":9},[809],{"nctId":208,"briefTitle":209,"status":90,"phases":810,"primaryCompletion":211,"completion":212,"start":213,"enrollment":127,"conditions":811,"interventions":812},[72],[28],[39,149,216],{"trials":814,"activeCount":9},[],{"trials":816,"activeCount":9},[],{"trials":818,"activeCount":9},[],{"intervention":820,"totalTrials":259,"cells":821},"BeEAM",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":823,"activeCount":9},[],{"trials":825,"activeCount":9},[],{"trials":827,"activeCount":9},[828],{"nctId":829,"briefTitle":830,"status":90,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":837},"NCT02416206","High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma",[72],"2020-03-26","2021-04-21","2015-04-27",65,[23],[820],{"trials":839,"activeCount":9},[],{"trials":841,"activeCount":9},[],{"trials":843,"activeCount":9},[]]